Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Perlman School of Medicine
mi
from
Philadelphia, PA
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Perlman School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Baptist Health Center for Clinical Research
mi
from
Little Rock, AR
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Baptist Health Center for Clinical Research
mi
from
Little Rock, AR
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Arthritis Associates of Southern California
mi
from
Los Angeles, CA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Arthritis Associates of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital
mi
from
Washington,
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
West Michigan Rheumatology
mi
from
Grand Rapids, MI
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
West Michigan Rheumatology
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
University of Texas- Houston Medical School
mi
from
Houston, TX
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
University of Texas- Houston Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Prevention-effectiveness Trial of DabirAIR Overlay System
A Point-of-care, Pragmatic Comparative Prevention-effectiveness Trial of DabirAIR Alternating Pressure Overlay System to Reduce Hospital-acquired Pressure Ulcers in the Peri-operative Setting.
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Comparative Prevention-effectiveness Trial of DabirAIR Overlay System
A Point-of-care, Pragmatic Comparative Prevention-effectiveness Trial of DabirAIR Alternating Pressure Overlay System to Reduce Hospital-acquired Pressure Ulcers in the Peri-operative Setting.
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI
Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI
Status: Enrolling
Updated:  12/31/1969
James J Peters VA Medical Center
mi
from
Bronx, NY
Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI
Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI
Status: Enrolling
Updated: 12/31/1969
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Phoenix Neurological Associates
mi
from
Phoenix, AZ
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Phoenix Neurological Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Vermont College of Medicine
mi
from
Burlington, VT
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Kansas
mi
from
Kansas City, KA
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Kansas
mi
from
Kansas City, KA
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Northwell Health
mi
from
Great Neck, NY
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Northwell Health
mi
from
Great Neck, NY
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Debrecen
mi
from
Debrecen,
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Debrecen
mi
from
Debrecen,
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated:  12/31/1969
George Washington University
mi
from
Washington,
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Bay Area Allergy
mi
from
Walnut Creek, CA
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Bay Area Allergy
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
IMMUNOe Research Centers
mi
from
Centennial, CO
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
IMMUNOe Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Asthma And Allergy Associates, P.C.
mi
from
Colorado Springs, CO
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Asthma And Allergy Associates, P.C.
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Clinical Research of Charlotte
mi
from
Charlotte, NC
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Clinical Research of Charlotte
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Bernstein Clinical Research Center
mi
from
Cincinnati, OH
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Bernstein Clinical Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions, LLC
mi
from
Middleburg Heights, OH
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions, LLC
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
Allergy Clinic of the Tulsa, Inc.
mi
from
Tulsa, OK
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Allergy Clinic of the Tulsa, Inc.
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated:  12/31/1969
AIRE Medical of Los Angeles
mi
from
Santa Monica, CA
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
AIRE Medical of Los Angeles
mi
from
Santa Monica, CA
Click here to add this to my saved trials